JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) and increased the price target from $26 to $30.
May 01, 2024 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama reaffirmed an Overweight rating on Kiniksa Pharmaceuticals and raised the price target to $30 from $26.
The upgrade in the price target by a reputable analyst like Anupam Rama from JP Morgan is a strong positive signal to the market, indicating a bullish outlook on Kiniksa Pharmaceuticals. Such endorsements typically lead to increased investor confidence and can drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100